NEU 2.99% $20.10 neuren pharmaceuticals limited

Share Price, page-60

  1. 2,831 Posts.
    lightbulb Created with Sketch. 592
    If you take the Guggenheim report at face value, that the re-rating is essentially because of the likelihood of trofinetide being approved, then by far the better option would be to buy NEU.

    I wonder whether the analyst points that out to his clients?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.